PL353960A1 - Cząsteczki przeciwciał swoiste wobec ludzkiego czyCząsteczki przeciwciał swoiste wobec ludzkiego czynnika martwicy nowotworów alfa oraz ich zastosowannnika martwicy nowotworów alfa oraz ich zastosowanieie - Google Patents

Cząsteczki przeciwciał swoiste wobec ludzkiego czyCząsteczki przeciwciał swoiste wobec ludzkiego czynnika martwicy nowotworów alfa oraz ich zastosowannnika martwicy nowotworów alfa oraz ich zastosowanieie

Info

Publication number
PL353960A1
PL353960A1 PL01353960A PL35396001A PL353960A1 PL 353960 A1 PL353960 A1 PL 353960A1 PL 01353960 A PL01353960 A PL 01353960A PL 35396001 A PL35396001 A PL 35396001A PL 353960 A1 PL353960 A1 PL 353960A1
Authority
PL
Poland
Prior art keywords
specificity
necrosis factor
tumor necrosis
antibody molecules
human tumor
Prior art date
Application number
PL01353960A
Other languages
English (en)
Other versions
PL212738B1 (pl
Inventor
Diljeet SinghAthwal Diljeet Singh Athwal
Derek ThomasBrown Derek Thomas Brown
Andrew Neil CharlesWeir Andrew Neil Charles Weir
Andrew GeorgePopplewell Andrew George Popplewell
Andrew PaulChapman Andrew Paul Chapman
David JohnKing David John King
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9893121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL353960(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of PL353960A1 publication Critical patent/PL353960A1/pl
Publication of PL212738B1 publication Critical patent/PL212738B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compression Of Band Width Or Redundancy In Fax (AREA)
PL353960A 2000-06-06 2001-06-05 Czasteczka przeciwciala, zwiazek, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania czasteczki przeciwciala, kompozycja terapeutyczna lub diagnostyczna, zastosowanie czasteczki przeciwciala albo zwiazku PL212738B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0013810.7A GB0013810D0 (en) 2000-06-06 2000-06-06 Biological products
PCT/GB2001/002477 WO2001094585A1 (en) 2000-06-06 2001-06-05 Antibody molecules having specificity for human tumor necrosis factor alpha, and use thereof

Publications (2)

Publication Number Publication Date
PL353960A1 true PL353960A1 (pl) 2003-12-15
PL212738B1 PL212738B1 (pl) 2012-11-30

Family

ID=9893121

Family Applications (2)

Application Number Title Priority Date Filing Date
PL399351A PL218516B1 (pl) 2000-06-06 2001-06-05 Cząsteczka przeciwciała, związek zawierający cząsteczkę przeciwciała, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania cząsteczki przeciwciała, kompozycja terapeutyczna lub diagnostyczna, zastosowanie cząsteczki przeciwciała albo związku
PL353960A PL212738B1 (pl) 2000-06-06 2001-06-05 Czasteczka przeciwciala, zwiazek, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania czasteczki przeciwciala, kompozycja terapeutyczna lub diagnostyczna, zastosowanie czasteczki przeciwciala albo zwiazku

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL399351A PL218516B1 (pl) 2000-06-06 2001-06-05 Cząsteczka przeciwciała, związek zawierający cząsteczkę przeciwciała, sekwencja DNA, wektor do klonowania lub ekspresji, komórka gospodarza, sposób wytwarzania cząsteczki przeciwciała, kompozycja terapeutyczna lub diagnostyczna, zastosowanie cząsteczki przeciwciała albo związku

Country Status (43)

Country Link
US (4) US7012135B2 (pl)
EP (4) EP2308975B1 (pl)
JP (3) JP4064812B2 (pl)
KR (1) KR20020047097A (pl)
CN (1) CN1289671C (pl)
AP (1) AP2092A (pl)
AR (1) AR033978A1 (pl)
AT (1) ATE451460T1 (pl)
AU (1) AU783756B2 (pl)
BE (1) BE2010C019I2 (pl)
BG (1) BG66072B1 (pl)
BR (2) BR0106682A (pl)
CA (2) CA2380298C (pl)
CY (6) CY1109889T1 (pl)
CZ (1) CZ300737B6 (pl)
DE (3) DE60140738D1 (pl)
DK (4) DK2230308T3 (pl)
EC (1) ECSP024210A (pl)
ES (5) ES2337763T3 (pl)
FR (1) FR10C0015I2 (pl)
GB (2) GB0013810D0 (pl)
HK (2) HK1051385A1 (pl)
HU (4) HU230561B1 (pl)
IL (3) IL147992A0 (pl)
IS (2) IS2808B (pl)
LT (1) LT2308975T (pl)
LU (1) LU91674I2 (pl)
MX (1) MXPA01013440A (pl)
MY (1) MY136603A (pl)
NL (1) NL300982I9 (pl)
NO (4) NO334808B1 (pl)
NZ (1) NZ516596A (pl)
OA (1) OA12282A (pl)
PE (1) PE20020292A1 (pl)
PL (2) PL218516B1 (pl)
PT (4) PT3059314T (pl)
RU (1) RU2303604C2 (pl)
SI (3) SI2230308T1 (pl)
SK (1) SK288343B6 (pl)
TR (1) TR201900227T4 (pl)
TW (2) TWI353358B (pl)
WO (1) WO2001094585A1 (pl)
ZA (1) ZA200200097B (pl)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0013810D0 (en) * 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
EP1495056B1 (en) * 2002-03-20 2011-03-02 UCB Pharma, S.A. Methods of analyzing antibody disulfide isomers
US20040009172A1 (en) * 2002-04-26 2004-01-15 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
US8153768B2 (en) 2002-05-02 2012-04-10 Wyeth Holdings Corporation Calicheamicin derivative-carrier conjugates
US7601817B2 (en) 2002-05-28 2009-10-13 Ucb Pharma S.A. Antibody peg positional isomers, compositions comprising same, and use thereof
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
KR20140058649A (ko) * 2002-07-19 2014-05-14 애브비 바이오테크놀로지 리미티드 ＴＮＦα 관련 질환의 치료
AU2003276844A1 (en) * 2002-08-28 2004-03-19 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
WO2004019861A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
US20040105858A1 (en) * 2002-08-29 2004-06-03 Kim Joanne Young Hee Kwak Diagnosis and treatment of infertility
MY150740A (en) 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
CN101899106A (zh) 2002-10-29 2010-12-01 阿纳福公司 三聚细胞因子的三聚结合蛋白
US7101978B2 (en) 2003-01-08 2006-09-05 Applied Molecular Evolution TNF-α binding molecules
US7575893B2 (en) * 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
WO2004074345A2 (en) * 2003-02-19 2004-09-02 Pharmacia Corporation Carbonate esters of polyethylene glycol activated by means of oxalate esters
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
PL1639011T3 (pl) * 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
WO2005014649A2 (en) * 2003-08-08 2005-02-17 Pharmacia Corporation Method for the preparation of molecules having antibody activity
ATE353969T1 (de) * 2003-08-13 2007-03-15 Sandoz Ag Expressionsvektoren, transformierte wirtszellen und fermentationsverfahren zur herstellung rekombinanter polypeptide
SI1656455T1 (sl) * 2003-08-13 2012-12-31 Sandoz Ag Postopek za čiščenje rekombinantnih polipeptidov
GB0319601D0 (en) 2003-08-20 2003-09-24 Sandoz Ag Production process
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
CN100393748C (zh) * 2003-11-06 2008-06-11 上海中信国健药业有限公司 全人源肿瘤坏死因子抗体，其制备方法以及药物组合物
KR100772800B1 (ko) * 2003-11-17 2007-11-01 주식회사유한양행 인간 종양괴사인자 α를 인식하는 단일클론항체의가변영역 및 이를 코딩하는 유전자
US7435799B2 (en) 2004-01-08 2008-10-14 Applied Molecular Evolution TNF-α binding molecules
CN100427504C (zh) * 2004-06-02 2008-10-22 北京天广实生物技术有限公司 TNFα高亲和力嵌合抗体及其用途
JP2008504356A (ja) * 2004-06-30 2008-02-14 ドマンティス リミテッド 炎症性疾患を治療するための組成物及び方法
GB0425972D0 (en) * 2004-11-25 2004-12-29 Celltech R&D Ltd Biological products
WO2006062776A2 (en) * 2004-11-29 2006-06-15 The Regents Of The University Of California Hydroxyapatite-binding peptides for bone growth and inhibition
JP4642862B2 (ja) * 2004-12-29 2011-03-02 ユーハン・コーポレイション ヒト腫瘍壊死因子−アルファに特異的なヒト化抗体
KR101465456B1 (ko) 2005-05-16 2014-11-27 애브비 바이오테크놀로지 리미티드 미란성 다발관절염의 치료를 위한 ｔｎｆ 억제제의 용도
AU2006254333B2 (en) * 2005-06-01 2011-02-17 Amgen Research (Munich) Gmbh Anti-IL2 antibodies
MX2007015280A (es) 2005-06-07 2008-04-08 Esbatech Ag Anticuerpos estables y solubles que inhiben tnf-alfa.
GB0520169D0 (en) 2005-10-04 2005-11-09 Celltech R&D Ltd Biological products
US9101670B2 (en) 2006-04-07 2015-08-11 Nektar Therapeutics Conjugates of an anti-TNF-α antibody
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
WO2007120656A2 (en) 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5385135B2 (ja) 2006-07-03 2014-01-08 チャールズ デイビッド アデア， 細胞接着分子の発現を調節するための組成物
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
WO2008109462A2 (en) * 2007-03-02 2008-09-12 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
JP2010532749A (ja) * 2007-06-07 2010-10-14 サーモディクス ファーマシューティカルズ， インコーポレイテッド 質量を削減した長時間作用剤形
EP2171451A4 (en) 2007-06-11 2011-12-07 Abbott Biotech Ltd METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
EP2185188B1 (en) 2007-08-22 2014-08-06 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
WO2015164330A1 (en) 2014-04-21 2015-10-29 Millennium Pharmaceuticals, Inc. Anti-psyk antibody molecules and use of same for syk-targeted therapy
AU2009212079B2 (en) * 2008-02-05 2012-08-30 Delenex Therapeutics Ag Antigen-binding polypeptides against cartilage degeneration
WO2009135861A2 (en) * 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
PL2307454T3 (pl) 2008-06-25 2017-07-31 Esbatech, An Alcon Biomedical Research Unit Llc Trwałe i rozpuszczalne przeciwciała hamujące VEGF
EP3858854A1 (en) * 2008-06-25 2021-08-04 Novartis AG Stable and soluble antibodies inhibiting tnf
HUE056007T2 (hu) 2008-06-25 2022-01-28 Novartis Ag Nyúl ellenanyagok humanizálása univerzális ellenanyagváz alkalmazásával
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
CN101684156B (zh) * 2008-09-27 2011-12-28 苏州工业园区晨健抗体组药物开发有限公司 人TNFα单克隆抗体、其PEG化纳米颗粒及其应用
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
CA2749966A1 (en) * 2009-01-29 2010-08-05 Abbott Laboratories Il-1 binding proteins
DK2451839T3 (da) 2009-07-10 2020-07-13 Ablynx Nv Fremgangsmåde til produktion af variable domæner
AU2010299640B2 (en) 2009-09-24 2016-02-25 Ucb Pharma S.A. Bacterial host strain
CA2774032C (en) 2009-10-23 2019-03-26 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and related compositions and methods
GB201000587D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000591D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
GB201000588D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000590D0 (en) 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201001791D0 (en) 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
EP2542258A4 (en) 2010-03-04 2013-08-21 Vet Therapeutics Inc MONOCLONAL ANTIBODIES DIRECTED AGAINST CD52
US9616120B2 (en) 2010-03-04 2017-04-11 Vet Therapeutics, Inc. Monoclonal antibodies directed to CD20
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
GB201012599D0 (en) * 2010-07-27 2010-09-08 Ucb Pharma Sa Process for purifying proteins
GB201012603D0 (en) 2010-07-27 2010-09-08 Ucb Pharma Sa Protein purification
GB201012784D0 (en) * 2010-07-29 2010-09-15 Ucb Pharma Sa Method
TWI538918B (zh) 2010-10-20 2016-06-21 財團法人工業技術研究院 人源化之單株抗體、其核苷酸序列與其用途
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
ES2676877T3 (es) 2011-06-01 2018-07-25 Intrexon Actobiotics Nv Sistema de expresión policistrónica para bacterias
EP2546267A1 (en) 2011-07-13 2013-01-16 UCB Pharma S.A. Bacterial host strain expressing recombinant DsbC
PL2731973T3 (pl) 2011-07-13 2018-04-30 Ucb Biopharma Sprl Bakteryjny szczep gospodarz wykazujący ekspresję dsbc
CA3131722A1 (en) 2011-09-23 2013-03-28 Intrexon Actobiotics Nv Modified gram positive bacteria and uses thereof
ES2676707T3 (es) 2011-09-23 2018-07-24 Intrexon Actobiotics Nv Bacterias gram positivas modificadas y usos de las mismas
WO2013087914A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
GB201208367D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2014028446A1 (en) 2012-08-13 2014-02-20 Genentech, Inc. Anti-jagged anitbodies and methods of use
EP3220961B1 (en) 2014-10-22 2023-07-05 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CA2969981C (en) 2014-12-22 2024-06-25 Ucb Biopharma Sprl A method for manufacturing a protein coupled to a peg molecule
EP3341021A4 (en) * 2015-08-27 2019-03-13 Celldex Therapeutics, Inc. ANTI-ALK ANTIBODIES AND METHOD OF USE THEREOF
GB201522394D0 (en) 2015-12-18 2016-02-03 Ucb Biopharma Sprl Antibodies
RU2760997C2 (ru) 2016-01-14 2021-12-02 Интрексон Актобиотикс Н.В. Композиции и способы для лечения диабета 1 типа
RU2680011C2 (ru) * 2016-04-29 2019-02-14 Закрытое Акционерное Общество "Биокад" Триспецифические антитела против il-17a, il-17f и другой провоспалительной молекулы
HUE054804T2 (hu) 2016-06-02 2021-09-28 Abbvie Inc Glükokortikoid receptor antagonista és annak immunkonjugátumai
PL3658192T3 (pl) 2017-12-01 2021-10-18 Abbvie Inc. Agonista receptora glukokortykoidowego i jego immunokoniugaty
CN113631574A (zh) 2019-01-31 2021-11-09 努玛治疗有限公司 对TNFα和IL-17A具有特异性的多特异性抗体、靶向IL-17A的抗体及其使用方法
KR102323342B1 (ko) * 2019-04-26 2021-11-08 주식회사 와이바이오로직스 IL-17A 및 TNF-α에 특이적으로 결합하는 이중표적 항체
CN111909268B (zh) * 2019-05-07 2022-04-19 北京天成新脉生物技术有限公司 低免疫原性低ADCC/CDC功能抗TNF-α人源化单克隆抗体TCX060及其应用
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
AU2022219373A1 (en) 2021-02-15 2023-08-24 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス（スーチョウ）カンパニー，リミティド ステロイド化合物及びそのコンジュゲート
SE545714C2 (en) * 2021-09-24 2023-12-19 Xbrane Biopharma Ab Dna contructs for producing a pelb signal peptide
SE545694C2 (en) * 2021-09-24 2023-12-05 Xbrane Biopharma Ab Dna construct comprising nucleotide sequences encoding amino acid sequences of certolizumab and pelb signal peptides
EP4405473A1 (en) 2021-09-24 2024-07-31 Xbrane Biopharma AB Dna constructs and host cells for expressing recombinant protein
WO2023154799A1 (en) 2022-02-14 2023-08-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination immunotherapy for treating cancer
WO2024180518A1 (en) * 2023-03-01 2024-09-06 Lupin Limited Process for manufacturing antibody fragment protein

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
US5030570A (en) 1988-06-30 1991-07-09 The Eunice Kennedy Shriver Center For Mental Retardation DNA encoding and method of expressing human monoamine oxidase type A
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (pt) * 1989-01-24 1990-07-31 Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
US5919452A (en) 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
NO309690B1 (no) 1995-01-23 2001-03-12 Western Atlas Int Inc Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
WO1996033204A1 (en) 1995-04-20 1996-10-24 The Kennedy Institute Of Rheumatology Multiple administrations of anti-tnf antibody
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) * 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6350860B1 (en) * 1997-08-18 2002-02-26 Innogenetics N.V. Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders
GB9720054D0 (en) * 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
GB9812545D0 (en) * 1998-06-10 1998-08-05 Celltech Therapeutics Ltd Biological products
GB0013810D0 (en) 2000-06-06 2000-07-26 Celltech Chiroscience Ltd Biological products

Also Published As

Publication number Publication date
EP1287140A1 (en) 2003-03-05
IS6217A (is) 2002-01-03
JP2003535591A (ja) 2003-12-02
NO20020554L (no) 2002-04-08
TW200817430A (en) 2008-04-16
GB2366800B (en) 2005-01-19
CY2010011I2 (el) 2012-01-25
SK3152002A3 (en) 2002-07-02
EP2308975B1 (en) 2016-08-10
SI2308975T1 (sl) 2016-11-30
NL300982I1 (pl) 2019-05-01
US20030026805A1 (en) 2003-02-06
TWI353358B (en) 2011-12-01
TWI316088B (en) 2009-10-21
IL195085A0 (en) 2009-08-03
TR201900227T4 (tr) 2019-02-21
EP3059314B1 (en) 2018-10-24
US7402662B2 (en) 2008-07-22
ZA200200097B (en) 2003-01-06
ES2600080T3 (es) 2017-02-07
CY1114143T1 (el) 2016-07-27
HUP1600016A2 (en) 2002-10-28
PT3059314T (pt) 2019-02-01
FR10C0015I1 (pl) 2010-04-16
LU91674I2 (fr) 2010-05-31
DK1287140T3 (da) 2010-04-19
NO341218B1 (no) 2017-09-11
HUP0202346A2 (en) 2002-10-28
DE10192353T1 (de) 2003-05-22
PE20020292A1 (es) 2002-05-08
JP2009171966A (ja) 2009-08-06
HK1148776A1 (en) 2011-09-16
HU230553B1 (hu) 2016-11-28
CZ2002837A3 (cs) 2002-05-15
NO20131316L (no) 2002-04-08
HU230669B1 (hu) 2017-07-28
GB0013810D0 (en) 2000-07-26
EP3059314A1 (en) 2016-08-24
ES2707714T3 (es) 2019-04-04
ES2403217T3 (es) 2013-05-16
CY1121173T1 (el) 2020-05-29
HU230561B1 (hu) 2016-12-28
NZ516596A (en) 2004-07-30
NO2014026I2 (no) 2018-02-14
AU783756B2 (en) 2005-12-01
EP1287140B1 (en) 2009-12-09
DK2308975T3 (da) 2016-10-31
CN1289671C (zh) 2006-12-13
FR10C0015I2 (fr) 2011-12-30
CY2019018I1 (el) 2020-05-29
PL212738B1 (pl) 2012-11-30
EP2230308A1 (en) 2010-09-22
US20080269465A1 (en) 2008-10-30
CZ300737B6 (cs) 2009-07-29
BE2010C019I2 (pl) 2020-08-20
DE60140738D1 (de) 2010-01-21
IL147992A (en) 2009-06-15
OA12282A (en) 2006-05-11
KR20020047097A (ko) 2002-06-21
PT2308975T (pt) 2016-11-14
PL399351A1 (pl) 2012-12-17
RU2303604C2 (ru) 2007-07-27
BRPI0106682B8 (pt) 2021-05-25
NO2014026I1 (no) 2014-10-23
HUP0202346A3 (en) 2004-11-29
US20060233800A1 (en) 2006-10-19
ECSP024210A (es) 2002-05-23
JP4064812B2 (ja) 2008-03-19
NL300982I9 (nl) 2019-05-06
MY136603A (en) 2008-10-31
CY2010011I1 (el) 2012-01-25
BRPI0106682B1 (pt) 2020-10-13
JP5185143B2 (ja) 2013-04-17
CA2707766C (en) 2013-05-21
HUP1600483A2 (pl) 2002-10-28
MXPA01013440A (es) 2003-09-04
WO2001094585A1 (en) 2001-12-13
LT2308975T (lt) 2016-11-10
PT2230308E (pt) 2013-05-03
BR0106682A (pt) 2002-05-14
ES2337763T3 (es) 2010-04-29
DE122010000027I1 (de) 2010-08-12
AU6051101A (en) 2001-12-17
NO20020554D0 (no) 2002-02-04
ATE451460T1 (de) 2009-12-15
AP2002002690A0 (en) 2002-12-31
CA2380298C (en) 2010-09-28
IL147992A0 (en) 2002-09-12
NO20160694A1 (no) 2002-04-08
CA2707766A1 (en) 2001-12-13
CY1118220T1 (el) 2017-06-28
ES2230975A1 (es) 2005-05-01
IS2808B (is) 2012-09-15
SI1287140T1 (sl) 2010-04-30
DK3059314T3 (en) 2019-02-18
SK288343B6 (sk) 2016-04-01
US20020151682A1 (en) 2002-10-17
US7012135B2 (en) 2006-03-14
DK2230308T3 (da) 2013-05-06
NO339282B1 (no) 2016-11-21
AR033978A1 (es) 2004-01-21
EP2230308B1 (en) 2013-01-23
HUS1700013I1 (hu) 2017-08-28
LU91674I9 (pl) 2019-01-03
BG66072B1 (bg) 2011-01-31
JP4476989B2 (ja) 2010-06-09
ES2230975B2 (es) 2007-04-16
GB2366800A (en) 2002-03-20
CA2380298A1 (en) 2001-12-13
AP2092A (en) 2010-02-28
PL218516B1 (pl) 2014-12-31
EP2308975A1 (en) 2011-04-13
HK1051385A1 (en) 2003-08-01
CN1383450A (zh) 2002-12-04
US7186820B2 (en) 2007-03-06
IS3016B (is) 2019-10-15
CY2019018I2 (el) 2020-05-29
JP2007105043A (ja) 2007-04-26
US7977464B2 (en) 2011-07-12
BG106278A (bg) 2002-12-29
PT1287140E (pt) 2010-03-08
SI2230308T1 (sl) 2013-06-28
GB0128386D0 (en) 2002-01-16
CY1109889T1 (el) 2012-01-25
NO334808B1 (no) 2014-06-02

Similar Documents

Publication Publication Date Title
HUS1700013I1 (hu) Humán tumor nekrózis faktor-alfa specifikus antitest molekulák és alkalmazásuk
EP2940044B8 (en) Anti-tnf alpha antibodies for use in therapy
HUP0400284A3 (en) Recombinant tumor specific antibody and use thereof
IL202332A0 (en) Liv-1 related protein, polynucleotides encoding the same and use thereof for treatment of cancer
GB0109537D0 (en) Well treatment fluids and methods for the use thereof
AU2868601A (en) Biaryl compounds, their preparation and their use in therapy
EP1437367A4 (en) ANTIBODIES AND ITS USE
AU2002357468A1 (en) Use of 2-acylindoles in the treatment of tumors
GB0022216D0 (en) Human FAP-a-specific antibodies for use in cancer therapy
AUPR073300A0 (en) Novel therapeutic molecules and uses therefor - V
AUPR073200A0 (en) Novel therapeutic molecules and uses therefor - VI
AUPR073000A0 (en) Novel therapeutic molecules and uses therefor - iv
AUPQ884400A0 (en) Novel therapeutic molecules and uses therefor - II
AUPQ670400A0 (en) Novel therapeutic molecules and uses therefor
AU2001228686A1 (en) Biaryl compounds, their preparation and their use in therapy